Straits Times Index
3,302.53 -11.52 (-0.35%) Nikkei
39,042.30 -27.38 (-0.07%) Hang Seng
19,251.85 -384.37 (-1.96%) FTSE 100
8,424.20 +3.94 (+0.05%) Bitcoin USD
70,872.01 +3,723.69 (+5.55%) CMC Crypto 200
1,523.57 +169.15 (+12.49%)
JW (Cayman) Therapeutics Co. Ltd (2126.HK)
| Previous close | 2.420 |
| Open | 2.600 |
| Bid | 2.290 x N/A |
| Ask | 2.300 x N/A |
| Day's range | 2.280 - 2.600 |
| 52-week range | 1.580 - 3.490 |
| Volume | |
| Avg. volume | 503,913 |
| Market cap | 944.738M |
| Beta (5Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.050 |
| Earnings date | 20 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.78 |
PR Newswire AsiaJW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed o
PR NewswireJW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy
JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development and commercialization of a chimeric antigen receptor (CAR) T-cell therapy product for autoimmune diseases (AID program) in Greater China.
Business Wire2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
CAMBRIDGE, Mass. & SHANGHAI, China, September 12, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, today announced their intention to expand their strategic alliance. The expansion, based on the partnership that was established last year, builds upon the companies’ translational and cli
